I suspect it may be important for people to know and understand just why Dalton took Univec dark and non-reporting. The cost of maintaining the current status in the healthcare industry can be extremely expensive, and the time required to fight patent infringement suits can truly wear people down.

I have seen reports that a million dollars or more can be spent even by a small company every year to be current, and if the company is not fully operational, that expense must be funded by debt borrowing --- typically not a good situation for penny or sub-penny stock companies.

As many may know I strongly suspect Dalton and Univec are still very much involved in the safety syringe business. Big pharma is heavily involved in this business, and they do not mind spending money to defend their turf. Thus, I suspect Doctor Dalton wants all the t’s and I’s crossed and dotted before he takes on the pharmaceutical industry. Also, patents do not last forever. Perhaps Dalton is waiting for a patent to expire or even a group of patents to expire before going current. The fact is, we don’t know the answer for why Dalton has not gone current. However, cost and legal issues are likely to be a major factor.

Kgem